During the past decade, Merck Sharp & Dohme Ilaclari Ltd. Sti conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Merck Sharp & Dohme Ilaclari Ltd. Sti" are "Metastatic Castration-Resistant Prostate Cancer" (1 trials) and "Postoperative Nausea and Vomiting" (1 trials). Many other conditions were trialed in "Merck Sharp & Dohme Ilaclari Ltd. Sti" in a lesser frequency.

Most popular intervention types in "Merck Sharp & Dohme Ilaclari Ltd. Sti" are "Drug" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abiraterone acetate 1000 mg" (1 trials), "Aprepitant" (1 trials), "Belzutifan 120mg" (1 trials), "Carboplatin" (1 trials) and "Dexamethasone 8 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Merck Sharp & Dohme Ilaclari Ltd. Sti" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Merck Sharp & Dohme Ilaclari Ltd. Sti". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Merck Sharp & Dohme Ilaclari Ltd. Sti, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Merck Sharp & Dohme Ilaclari Ltd. Sti, 2 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".